-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company
PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) , the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., entered into a supply agreement with one of the largest phyto-therapeutic companies in the Brazilian market. The customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transparent business model that measures social and environmental impacts.
PharmaCielo will be registered with Anvisa as the sole supplier to the customer for this product, and under the agreement, PharmaCielo will ship significant quarterly volumes of a proprietary CBD derivative formulation to the Customer, which will be utilized in the production of novel herbal medicines to be distributed across Latin America. The company expects to begin shipping during Q1 2023.
Management Changes
PharmaCielo has appointed Ian D. Atacan to its board of directors. Atacan has been the company's CFO since June 7, 2021.
PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as chief medical officer of the company, to advance the company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally.
Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school.
Photo: Benzinga; Sources: geralt, lindsayfox via Pixabay
Related News
PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Compan
PharmaCielo Q1 Revenue Increases 77.92% YoY, Discusses International Market
PharmaCielo Enters Spanish Market With Initial Shipment Of 300Kg Of CBD Full Spectrum Oil To Extractions Solutions
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) , the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., entered into a supply agreement with one of the largest phyto-therapeutic companies in the Brazilian market. The customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transparent business model that measures social and environmental impacts.
PharmaCielo Ltd.(OTCQX：PCLOF)(多倫多證券交易所股票代碼：PCLO)，哥倫比亞乾花和藥用級大麻提取物的主要種植者和生產商的加拿大母公司，PharmaCielo哥倫比亞控股公司, 簽訂了A供貨協議與世界上最大的巴西市場上的植物治療公司。該客户在拉丁美洲擁有廣泛的分銷網絡，也是經過認證的B-Corp，反映了其對衡量社會和環境影響的透明商業模式的承諾。
PharmaCielo will be registered with Anvisa as the sole supplier to the customer for this product, and under the agreement, PharmaCielo will ship significant quarterly volumes of a proprietary CBD derivative formulation to the Customer, which will be utilized in the production of novel herbal medicines to be distributed across Latin America. The company expects to begin shipping during Q1 2023.
PharmaCielo將在Anvisa註冊為該產品客户的唯一供應商，根據協議，PharmaCielo將每季度向客户發運大量專有CBD衍生配方，這些配方將用於生產將在拉丁美洲分銷的新型草藥。該公司預計將於2023年第一季度開始發貨。
Management Changes
管理層變動
PharmaCielo has appointed Ian D. Atacan to its board of directors. Atacan has been the company's CFO since June 7, 2021.
PharmaCielo已任命伊恩·D·阿塔坎提交給其董事會。阿塔坎自2021年6月7日以來一直擔任該公司的首席財務官。
PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as chief medical officer of the company, to advance the company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally.
PharmaCielo已任命Decio Rabelo de Castro Filho博士AS首席醫療官為了提高公司在醫生羣體中的知名度，以及在拉丁美洲、歐洲和全球其他關鍵市場的製藥組織中的知名度。
Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school.
德·卡斯特羅·菲略博士是一名醫生，在職業醫學和市場營銷方面擁有20多年的經驗。在他的職業生涯中，德·卡斯特羅·菲略博士還曾為幾家巴西大公司擔任過專家醫學證人。德·卡斯特羅·菲略博士畢業於坎皮納斯天主教教皇大學的醫學課程，並擁有聖保羅Escola Superior de Promotion e Marketing ESPM的市場營銷碩士學位。他擁有韋肯學院大麻類藥物的學位。
Photo: Benzinga; Sources: geralt, lindsayfox via Pixabay
圖片來源：Geralt，lindsayfox
Related News
相關新聞
PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Compan
PharmaCielo向一家巴西製藥公司運送CBD全光譜油
PharmaCielo Q1 Revenue Increases 77.92% YoY, Discusses International Market
PharmaCielo第一季度營收同比增長77.92%，探討國際市場
PharmaCielo Enters Spanish Market With Initial Shipment Of 300Kg Of CBD Full Spectrum Oil To Extractions Solutions
PharmaCielo以首批300公斤CBD全光譜油進入西班牙市場
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧